vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $164.7M, roughly 1.3× PTC THERAPEUTICS, INC.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -82.0%, a 139.3% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $-36.6M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
IDYA vs PTCT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $164.7M |
| Net Profit | $119.2M | $-135.0M |
| Gross Margin | — | — |
| Operating Margin | 52.2% | -43.3% |
| Net Margin | 57.4% | -82.0% |
| Revenue YoY | — | -22.7% |
| Net Profit YoY | 330.1% | -104.8% |
| EPS (diluted) | $1.33 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $164.7M | ||
| Q3 25 | $207.8M | $211.0M | ||
| Q2 25 | — | $178.9M | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $213.2M | ||
| Q3 24 | $0 | $196.8M | ||
| Q2 24 | $0 | $186.7M | ||
| Q1 24 | $0 | $210.1M |
| Q4 25 | — | $-135.0M | ||
| Q3 25 | $119.2M | $15.9M | ||
| Q2 25 | — | $-64.8M | ||
| Q1 25 | — | $866.6M | ||
| Q4 24 | — | $-65.9M | ||
| Q3 24 | $-51.8M | $-106.7M | ||
| Q2 24 | $-52.8M | $-99.2M | ||
| Q1 24 | $-39.6M | $-91.6M |
| Q4 25 | — | -43.3% | ||
| Q3 25 | 52.2% | 1.4% | ||
| Q2 25 | — | -19.5% | ||
| Q1 25 | — | 82.5% | ||
| Q4 24 | — | -76.2% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -21.5% | ||
| Q1 24 | — | -21.6% |
| Q4 25 | — | -82.0% | ||
| Q3 25 | 57.4% | 7.5% | ||
| Q2 25 | — | -36.3% | ||
| Q1 25 | — | 73.7% | ||
| Q4 24 | — | -30.9% | ||
| Q3 24 | — | -54.2% | ||
| Q2 24 | — | -53.1% | ||
| Q1 24 | — | -43.6% |
| Q4 25 | — | $-1.63 | ||
| Q3 25 | $1.33 | $0.20 | ||
| Q2 25 | — | $-0.83 | ||
| Q1 25 | — | $10.04 | ||
| Q4 24 | — | $-0.85 | ||
| Q3 24 | $-0.60 | $-1.39 | ||
| Q2 24 | $-0.68 | $-1.29 | ||
| Q1 24 | $-0.53 | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $-205.3M |
| Total Assets | $1.2B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.9B | ||
| Q3 25 | $786.9M | $1.7B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $920.0M | $1.0B | ||
| Q2 24 | $701.7M | $1.1B | ||
| Q1 24 | $698.8M | $884.8M |
| Q4 25 | — | $-205.3M | ||
| Q3 25 | $1.1B | $-155.8M | ||
| Q2 25 | — | $-206.5M | ||
| Q1 25 | — | $-185.8M | ||
| Q4 24 | — | $-1.1B | ||
| Q3 24 | $1.2B | $-1.1B | ||
| Q2 24 | $931.7M | $-980.2M | ||
| Q1 24 | $935.3M | $-893.9M |
| Q4 25 | — | $2.9B | ||
| Q3 25 | $1.2B | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $1.2B | $1.8B | ||
| Q2 24 | $973.7M | $1.9B | ||
| Q1 24 | $961.5M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $-34.3M |
| Free Cash FlowOCF − Capex | $142.2M | $-36.6M |
| FCF MarginFCF / Revenue | 68.4% | -22.3% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-34.3M | ||
| Q3 25 | $142.2M | $-66.3M | ||
| Q2 25 | — | $-58.3M | ||
| Q1 25 | — | $870.1M | ||
| Q4 24 | — | $-30.0M | ||
| Q3 24 | $-49.2M | $-77.0M | ||
| Q2 24 | $-32.9M | $-71.5M | ||
| Q1 24 | $-43.8M | $70.8M |
| Q4 25 | — | $-36.6M | ||
| Q3 25 | $142.2M | $-69.7M | ||
| Q2 25 | — | $-59.6M | ||
| Q1 25 | — | $868.4M | ||
| Q4 24 | — | $-33.8M | ||
| Q3 24 | $-49.7M | $-77.5M | ||
| Q2 24 | $-33.9M | $-78.8M | ||
| Q1 24 | $-45.1M | $61.2M |
| Q4 25 | — | -22.3% | ||
| Q3 25 | 68.4% | -33.1% | ||
| Q2 25 | — | -33.3% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | -15.8% | ||
| Q3 24 | — | -39.4% | ||
| Q2 24 | — | -42.2% | ||
| Q1 24 | — | 29.1% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 4.0% | ||
| Q1 24 | — | 4.6% |
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | -4.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
